In last trading session, scPharmaceuticals Inc (NASDAQ:SCPH) saw 0.57 million shares changing hands with its beta currently measuring 0.20. Company’s recent per share price level of $2.32 trading at $0.02 or 0.87% at ring of the bell on the day assigns it a market valuation of $116.66M. That closing price of SCPH’s stock is at a discount of -143.53% from its 52-week high price of $5.65 and is indicating a premium of 5.17% from its 52-week low price of $2.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.52 million shares which gives us an average trading volume of 423.70K if we extend that period to 3-months.

For scPharmaceuticals Inc (SCPH), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.28 in the current quarter.

scPharmaceuticals Inc (NASDAQ:SCPH) trade information

Upright in the green during last session for gaining 0.87%, in the last five days SCPH remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $2.32 price level, adding 16.25% to its value on the day. scPharmaceuticals Inc’s shares saw a change of -34.46% in year-to-date performance and have moved -16.40% in past 5-day. scPharmaceuticals Inc (NASDAQ:SCPH) showed a performance of -25.64% in past 30-days. Number of shares sold short was 5.67 million shares which calculate 9.55 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 13 to the stock, which implies a rise of 82.15% to its current value. Analysts have been projecting 13 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would drop -460.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -460.34% for stock’s current value.

scPharmaceuticals Inc (SCPH) estimates and forecasts

This year revenue growth is estimated to rise 109.80% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.63M for the same. And 5 analysts are in estimates of company making revenue of 16.43M in the next quarter. Company posted 6.1M and 8.05M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.52% during past 5 years.

scPharmaceuticals Inc (NASDAQ:SCPH)’s Major holders

Insiders are in possession of 11.16% of company’s total shares while institution are holding 84.89 percent of that, with stock having share float percentage of 95.56%. Investors also watch the number of corporate investors in a company very closely, which is 84.89% institutions for scPharmaceuticals Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at SCPH for having 5.56 million shares of worth $24.18 million. And as of 2024-06-30, it was holding 14.2608 of the company’s outstanding shares.

The second largest institutional holder is RUBRIC CAPITAL MANAGEMENT LP, which was holding about 3.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.042 of outstanding shares, having a total worth of $15.33 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.14 shares of worth $2.64 million or 2.26% of the total outstanding shares. The later fund manager was in possession of 854.33 shares on Feb 28, 2025 , making its stake of worth around $1.98 million in the company or a holder of 1.70% of company’s stock.